• Explore /
  • Poster
  • / Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia.

Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia.

Abstract Poster

Authors

null

Nicholas James Short

Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Nicholas James Short , Hagop M. Kantarjian , Susan Mary O'Brien , Farhad Ravandi , Deborah A. Thomas , Guillermo Garcia-Manero , Naval Guastad Daver , Gautam Borthakur , Nitin Jain , Marina Konopleva , Koji Sasaki , Naveen Pemmaraju , Yesid Alvarado , Jovitta Jacob , Rebecca Garris , Philip A. Thompson , Jorge E. Cortes , Elias Jabbour

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT01371630

Citation

J Clin Oncol 35, 2017 (suppl; abstr 7014)

DOI

10.1200/JCO.2017.35.15_suppl.7014

Abstract #

7014

Poster Bd #

214

Abstract Disclosures

Similar Posters

First Author: Elias Jabbour

First Author: Rita Assi

First Author: Nicholas James Short

First Author: Abdul Hamid Bazarbachi